AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Chairman’s report (verbal update)

5. Minutes of previous meeting

6. Appraisal 1: Full Submission
   Argatroban (Exembol®) for anticoagulation in adult patients with
   heparin-induced thrombocytopaenia type II who require parental
   antithrombotic therapy

7. Appraisal 2: Full Submission
   Eplerenone (Inspira®) in addition to standard optimal therapy, to
   reduce the risk of cardiovascular mortality and morbidity in adult
   patients with NYHA class II (chronic) heart failure and left ventricular
   systolic dysfunction (LVEF≤30%)

8. Appraisal 3: Limited Submission
   Sildenafil citrate (Revatio®) for the treatment of paediatric patients
   aged 1 year to 17 years old with pulmonary arterial hypertension.
   Efficacy in terms of improvement of exercise capacity or pulmonary
   haemodynamics has been shown in primary pulmonary hypertension
   and pulmonary hypertension associated with congenital heart disease

9. Appraisal 4: Limited Submission
   Bortezomib (Velcade®) for the treatment of progressive multiple
   myeloma in patients who have received at least one prior therapy and
   who have already undergone or are unsuitable for bone marrow
   transplantation

10. AWPAG Update (draft minutes – October 2012)


12. Date of next meeting:
   Wednesday, 6th February 2013 at Cardiff Metropolitan University